A unique company creation vehicle initiated by Lightstone Ventures and Evotec SE, and established with partners ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund

由Lightstone Ventures和Evotec SE发起并与合作伙伴ClavystBio，拜耳，Polaris合作伙伴和Polaris创新基金飞跃而成的独特公司创造载体

First-of-its-kind partnership in Singapore and Asia leverages breakthrough science from researchers at the Agency for Science, Technology and Research (A*STAR), the National University of Singapore (NUS) and Duke-NUS Medical School, for global health impact

新加坡和亚洲的一流合作伙伴关系利用了科学技术研究局（A*STAR），新加坡国立大学（NUS）和杜克-国立大学医学院的研究人员提供的突破性科学，对全球健康产生影响

New incubator will accelerate translation of promising academic projects to commercialization through creation of new companies focused on breakthrough therapeutics and support the growth of Singapore's biotech ecosystem

新孵化器将通过创建专注于突破性治疗的新公司并支持新加坡生物技术生态系统的发展，加速将有前途的学术项目转化为商业化项目

SINGAPORE, Oct. 5, 2023 /PRNewswire/ -- Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund, along with global life science company Evotec SE, today announced the launch of 65LAB to advance drug discovery and the creation of new therapeutics companies in Singapore..

新加坡，2023年10月5日/PRNewswire/-Lightstone Ventures，ClavystBio，拜耳，Polaris Partners和Polaris创新基金的飞跃，以及全球生命科学公司Evotec SE，今天宣布启动65LAB以推进药物发现和在新加坡创建新的治疗公司。。

The first collaboration of its kind in Singapore, 65LAB was initiated by Lightstone Ventures with Evotec to leverage the global capabilities of its partners – including financing, networks, company creation, and drug development expertise -- to identify and accelerate the commercialization of the most promising research from top academic and R&D institutions in Singapore, the Agency for Science, Technology and Research (A*STAR), the National University of Singapore (NUS) and Duke-NUS Medical School (a collaboration between Duke University and NUS).

65LAB在新加坡的首次合作是由Lightstone Ventures与Evotec共同发起的，旨在利用其合作伙伴的全球能力-包括融资，网络，公司创建和药物开发专业知识-来确定和加速最有希望的商业化来自新加坡顶级学术和研发机构的研究，科学技术研究局（A*STAR），新加坡国立大学（NUS）和杜克-国立大学医学院（杜克大学与国立大学合作）。

65LAB aims to combine Evotec's end-to-end integrated R&D platform and product development strength with Singapore's first-class academic and translational science, it's growing biotech infrastructure and capabilities to ultimately create breakthrough therapies with a global health impact..

65LAB旨在将Evotec的端到端集成研发平台和产品开发优势与新加坡一流的学术和转化科学相结合，它正在发展生物技术基础设施和能力，最终创造具有全球健康影响的突破性疗法。。

65LAB was founded to establish a model of long-term partnership to foster future company growth and the development of Singapore's biotech ecosystem. 65LAB selects promising academic projects and invests up to US$1.5 million in each project over the course of 18-24 months. The collaboration enables scientists in partner institutions to accelerate their therapeutic innovations through the support of Evotec's Expert-in-Residence, as well as direct access to the life science company's drug discovery, translational and development capabilities across disease areas and therapeutic modalities.

65LAB成立旨在建立长期合作模式，促进未来公司成长和新加坡生物技术生态系统的发展。65LAB选择有前途的学术项目，并在18-24个月内为每个项目投资150万美元。这种合作使合作机构的科学家能够通过Evotec的住院专家的支持加速他们的治疗创新，并直接访问生命科学公司的药物发现，跨疾病领域的转化和开发能力以及治疗方式。

Upon completion, projects will be evaluated by 65LAB's board of global investors for further investment and the creation of new companies..

项目完成后，将由65LAB的全球投资者委员会进行评估，以进一步投资和创建新公司。。

The core of the 65LAB collaboration is its Singapore-based academic and R&D partners, whose research discoveries will be translated with the goal to potentially achieve commercial success and create positive patient impact. Singapore's public sector academic and translational researchers bring expertise across multiple modalities of treatment and disease areas of high unmet need.

65LAB合作的核心是其位于新加坡的学术和研发合作伙伴，其研究发现将被翻译，目标是潜在地实现商业成功并创造积极的患者影响。新加坡的公共部门学术和转化研究人员为多种未满足需求的治疗和疾病领域带来专业知识。

Dr. Koh Shuwen, Director, Technology Transfer and Innovation, NUS Enterprise, said: '65LAB embodies the spirit of academic and industry collaboration, successfully translating the University's intellectual property for use and adoption by the industry. This collaboration offers NUS and our partners an opportunity to accelerate innovation by engaging the industry at an early stage of deep technology development.' Assistant Professor David Wang, Director of the Centre for Technology and Development, Duke-NUS Medical School, added: 'As a research powerhouse, Duke-NUS is committed to translating academic discoveries into clinical products, and I am confident that our collaboration with 65LAB will enable us to take that to a new level.' Ms.

国大企业技术转让与创新总监高淑文博士说：“65LAB体现了学术产业合作精神，成功翻译了大学知识产权供业界使用和采用。这项合作为国大集团和我们的合作伙伴提供了一个机会，通过在深度技术发展的早期阶段吸引行业来加速创新杜克-新加坡国立大学医学院技术与发展中心主任助理教授David Wang补充说：“作为一个研究中心，杜克-新加坡国立大学致力于将学术发现转化为临床产品，我相信我们与65LAB的合作将使我们能够把这一点提升到一个新的水平。”太太

Irene Cheong, Executive Director of A*STAR's Innovation & Enterprise Group said, 'A*STAR is pleased to partner 65LAB and support the translation of novel biomedical discoveries from bench to bedside for the benefit of patients in Singapore and beyond. As a strategic innovation engine for Singapore's R&D ecosystem, we look forward to contributing to the growth of the local biotech ecosystem.'.

A*STAR创新与企业集团执行董事Irene Cheong表示，“A*STAR很高兴与65LAB合作，并支持从实验室到床边的新型生物医学发现的翻译，为新加坡及其他地区的患者带来益处。作为新加坡研发生态系统的战略创新引擎，我们期待为当地生物技术生态系统的发展做出贡献。

65LAB's Board of Directors is a team of world-leading biotech investors with broad expertise in company building and advancing a broad range of therapeutic modalities into and through the clinic. The Board provides oversight and governance to 65LAB's strategy and operations and includes Dr. Wen Qi Ho, Therapeutics Lead, ClavystBio, Dr.

65LAB董事会是一个由世界领先的生物技术投资者组成的团队，他们在公司建设和推进广泛的治疗方式方面拥有广泛的专业知识。董事会为65LAB的战略和运营提供监督和治理，包括Ho-Qi博士，ClavystBio博士，治疗主管。

Christina Isacson, Partner, Lightstone Ventures, Dr. Pei Sze Ng, Director, Leaps by Bayer, and Dr. Kim Png, Principal, Polaris Partners..

合作伙伴Christina Isacson，Lightstone Ventures，拜耳飞跳总监Pei Sze Ng博士和Polaris合作伙伴首席Kim Png博士。。

Dr. Christina Isacson, Partner, Lightstone Ventures, said: 'Lightstone has long been committed to supporting the growth of Singapore's promising biotech sector, and we are thrilled at this opportunity to continue to foster and invest in the exciting drug development research coming out of the country's universities.

Lightstone Ventures的合作伙伴克里斯蒂娜·伊萨森博士说：“Lightstone长期以来一直致力于支持新加坡有前途的生物技术领域的发展，我们对此机会充满兴奋，继续培养和投资来自新加坡的令人兴奋的药物开发研究。该国的大学。

65LAB is a unique entity, whose key differentiator is the syndicate of seasoned global life science investors who recognize the untapped potential of Singapore's excellent base of scientific talent. We are pleased to partner with such a distinguished group of investors, who bring significant resources, experience and networks to transform these innovations into new medicines and bring them to market.'.

65LAB是一个独特的实体，其主要差异化者是经验丰富的全球生命科学投资者集团，他们认识到新加坡优秀科学人才基础的未开发潜力。我们很高兴与这样一批杰出的投资者合作，他们带来了大量的资源，经验和网络，将这些创新转化为新药并将其推向市场。

Dr. Thomas Hanke, EVP Head of Academic Partnerships at Evotec, said: 'Singapore has multiple world-renowned institutions for basic research in the life sciences. Through 65LAB, we are looking forward to translating their ground-breaking research into product candidates and new company formations that will benefit patients with unmet medical needs across all modalities and therapeutic areas.'.

Evotec学术合作伙伴关系负责人Thomas Hanke博士说：“新加坡拥有多个世界知名的生命科学基础研究机构。通过65LAB，我们期待将他们开创性的研究转化为产品候选人和新公司组建，这将有助于所有模式和治疗领域未满足医疗需求的患者。

About 65LAB65LAB was founded to turn innovations into lifesaving medicines. Our mission is to drivescientific advancement and create new therapeutic companies from Singapore. We accelerate the drug discovery pathway and new company formation by bringing together the expertise of global partners — leading research institutions in Singapore, established life science investors, and reputed drug discovery and development company Evotec.

大约65LAB65LAB的成立旨在将创新转化为救生药物。我们的使命是推动科学进步并从新加坡创建新的治疗公司。我们通过汇集全球合作伙伴的专业知识-新加坡领先的研究机构，成熟的生命科学投资者以及知名的药物发现与开发公司Evotec，加速了药物发现途径和新公司的形成。

65 pays homage to the year Singapore became an independent nation. It is also Singapore's country code. 65lab.sg .

65纪念新加坡成为独立国家的那一年。这也是新加坡的国家代码。65lab.sg。

Additional Quotes

其他报价

Dr. Khoo Shih, Chief Executive Officer, ClavystBio, said: '65LAB unites private and public sector players in a shared vision. ClavystBio's mission is to accelerate the commercialization of life sciences innovations through venture building and creating partnerships, and we're excited to be supporting the development of scientific talent and innovations at Singapore's leading academic and R&D institutions to enable new venture creation and grow our ecosystem.'.

ClavystBio首席执行官Khoo Shih博士说：“65LAB将私营和公共部门的参与者联合在一起。ClavystBio的使命是通过风险建设和建立伙伴关系加速生命科学创新的商业化，我们很高兴支持新加坡领先的学术和研发机构开发科学人才和创新，以实现新的风险创造和发展我们的生态系统。''。

Dr. Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business Development, Licensing & Open Innovation, said: 'We are thrilled to invest in Asia alongside a top-tier syndicate to tap into the remarkable science talent in Singapore and beyond. Leaps' mission is to solve ten of humanity's biggest challenges through investing in teams pursuing fundamental breakthroughs.

拜耳和制药业务发展，许可和开放创新领先的EVP Juergen Eckhardt博士表示：“我们很高兴与顶级集团一起投资亚洲，以利用新加坡及其他地区卓越的科学人才。Leaps的使命是通过投资追求根本突破的团队来解决人类面临的十大挑战。

Neither innovation nor disease knows geographic boundaries, and as such, we seek to support the best and brightest minds around the world for the benefit of patients and eagerly await the advancements poised to come out of 65LAB.'.

创新和疾病都不知道地理界限，因此，我们寻求支持世界各地最聪明，最聪明的头脑，为患者带来利益，并急切地等待即将从65LAB中脱颖而出的进步。

Amy Schulman, Managing Partner of Polaris Partners and the Polaris Innovation Fund, said: 'Singapore has a burgeoning biotech ecosystem, including a wealth of academic science that is hungry to be translated. 65LAB will play an important role in bringing development capabilities and expertise to facilitate the translation of these innovative IP.

北极星合作伙伴和北极星创新基金的管理伙伴艾米·舒尔曼（Amy Schulman）说：“新加坡拥有一个新兴的生物技术生态系统，其中包括丰富的学术科学，渴望被翻译。65LAB将在培养发展能力和专业知识方面发挥重要作用，促进这些创新知识产权的翻译。

Together with our academic and investor partners, we look forward to supporting the development of new medicines and innovations that will benefit patients globally.'.

与我们的学术和投资者合作伙伴一起，我们期待支持新药和创新的开发，这将使全球患者受益。

About ClavystBioClavystBio's mission is to accelerate the commercialization of life sciences breakthroughs into health impact. We invest and partner with innovators, entrepreneurs and founders to launch and grow global companies in Singapore. We foster partnerships among academics, industry and investors, and convene life sciences communities at our collaborative innovation space Node 1.

关于ClavystBioClavystBio的使命是加速生命科学突破对健康影响的商业化。我们与创新者，企业家和创始人投资并合作，在新加坡启动和发展全球公司。我们促进学者，行业和投资者之间的合作关系，并在我们的合作创新空间节点1召集生命科学界。

Together, we advance Singapore as a global life sciences translational hub. www.clavystbio.com.

我们共同推动新加坡成为全球生命科学转化中心。www.clavystbio.com。

About Lightstone Ventures Lightstone Ventures is a global venture capital fund dedicated to translating novel scientific breakthroughs into clinically and commercially meaningful therapies. We invest in biotech and medtech companies pioneering the big ideas poised to transform patient outcomes. We were founded in 2012 to empower visionary entrepreneurs with the resources and operational guidance necessary to bring innovative therapeutics and technologies to the people who need them most.

关于Lightstone Ventures Lightstone Ventures是一家全球风险投资基金，致力于将新的科学突破转化为具有临床和商业意义的疗法。我们投资于生物技术和medtech公司，这些公司开创了有望改变患者预后的大思想。我们成立于2012年，旨在为有远见的企业家提供必要的资源和运营指导，以便为最需要他们的人带来创新的治疗和技术。

Our investment team has led deals resulting in 19 acquisitions and 20 initial public offerings over the last two decades. We have offices in Boston, Mass., Menlo Park, Calif., and Dublin, Ireland. www.lightstonevc.com.

我们的投资团队在过去二十年中领导了19次收购和20次首次公开发行。我们在马萨诸塞州波士顿，加利福尼亚州门洛帕克和爱尔兰都柏林设有办事处。www.lightstonevc.com。

About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of today's biggest challenges in health and agriculture. The investment portfolio includes more than 50 companies. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. www.leaps.bayer.com.

拜耳的飞跃拜耳公司的一个单位拜耳领先，为解决当今健康和农业方面的一些最大挑战带来了影响投资。投资组合包括50多家公司。他们都在研究潜在的突破性技术，以克服一些具体挑战，例如发展可持续的蛋白质供应，减少农业对环境的影响，预防或治愈癌症等。www.leaps.bayer.com。

About Polaris Partners and Polaris Innovation FundPolaris Partners has a 25-plus-year history of partnering with repeat entrepreneurs and world-class innovators who are improving the way we live and work. The multibillion-dollar firm manages specialty and diversified funds in healthcare and technology with investments across all stages.

关于北极星合作伙伴和北极星创新FundPolaris合作伙伴有25年以上的历史，与正在改善我们生活和工作方式的重复企业家和世界一流创新者合作。这家价值数十亿美元的公司通过各个阶段的投资管理医疗保健和技术领域的专业和多元化资金。

Polaris Innovation Fund aims to accelerate the commercial and therapeutic potential of early-stage academic research. By partnering with passionate entrepreneurs with transformational science, Polaris Innovation Fund fosters company creation and growth through an active investment model. www.polarispartners.com .

北极星创新基金旨在加速早期学术研究的商业和治疗潜力。通过与充满激情的企业家与转型科学合作，北极星创新基金通过积极的投资模式促进公司的创建和发展。www.polarisparters.com。

About Evotec SEEvotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products.

关于Evotec SEEvotec是一家拥有独特商业模式的生命科学公司，致力于发现和开发高效疗法并将其提供给患者。该公司的多模式平台包括创新技术，数据和科学的独特组合，用于发现，开发和生产一流和一流的药品。

Evotec leverages this 'Data-driven R&D Autobahn to Cures' for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g.

Evotec利用这一“数据驱动的研发Autobahn治愈”用于专有项目以及合作伙伴网络，包括所有前20名制药公司和800多家生物技术公司，学术机构以及其他医疗保健利益相关者。Evotec在广泛的目前服务不足的治疗领域开展战略活动，包括。

neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world's leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development.

神经病学，肿瘤学以及代谢和传染病。在这些专业领域，Evotec旨在为创新疗法创建全球领先的合资管道，迄今为止，已建立了从早期发现到临床开发的200多个专有和合资研发项目组合。

Evotec operates globally with more than 5,000 highly qualified people. The Company's 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. www.evotec.com.

Evotec在全球运营，拥有5000多名高素质人士。该公司的17个站点提供高度协同的技术和服务，并作为卓越的互补集群运营。www.evotec.com。

About the Agency for Science, Technology and ResearchThe Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry.

关于科学技术研究机构科学技术研究机构（A*STAR）是新加坡领先的公共部门研发机构。通过开放式创新，我们与公共和私营部门的合作伙伴合作，使经济和社会受益。作为一个科学技术组织，a*明星弥合了学术界和工业界的鸿沟。

Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis.

我们的研究为新加坡创造了经济增长和就业机会，并通过改善医疗保健，城市生活和可持续性方面的社会成果来改善生活。A*STAR在培养更广泛的研究界和行业的科学人才和领导者方面发挥着关键作用。A*STAR的研发活动涵盖生物医学科学，物理科学和工程，研究实体主要位于Biopolis和Fusionopolis。

For ongoing news, visit www.a-star.edu.sg..

有关正在进行的新闻，请访问www.a-star.edu.sg。。

About Duke-NUS Medical SchoolDuke-NUS is Singapore's flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond.

关于杜克-新加坡国立大学医学院杜克-新加坡国立大学是新加坡的旗舰研究生入学医学院，成立于2005年，由两所世界级机构（杜克大学医学院和新加坡国立大学（NUS））建立由政府领导的战略性合作伙伴关系。通过创新的课程，杜克大学的学生得到培养，成为多方面的“临床医生加”，准备指导新加坡及其他地区的医疗保健和生物医学生态系统。

A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group.

国大杜克大学是开创性研究和转化创新的领导者，通过其五项标志性研究计划和十个中心获得了国际知名度。其发现的持久影响因其与新加坡最大的医疗集团新加坡卫生服务（SingHealth）成功的学术医学合作伙伴关系而得到放大。

This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. www.duke-nus.edu.sg.

这个战略联盟催生了15个学术临床项目，利用多学科的研究和教育来改变医学和改善生活。www.duke-nus.edu.sg。

About National University of Singapore (NUS)The National University of Singapore (NUS) is Singapore's flagship university, which offers a global approach to education, research and entrepreneurship, with a focus on Asian perspectives and expertise. We have 16 colleges, faculties and schools across three campuses in Singapore, with more than 40,000 students from 100 countries enriching our vibrant and diverse campus community.

关于新加坡国立大学（NUS），新加坡国立大学（NUS）是新加坡的旗舰大学，提供全球教育，研究和创业方法，重点关注亚洲的观点和专业知识。我们在新加坡的三所校园内设有16所大学，学院和学校，来自100个国家的40000多名学生丰富了我们充满活力和多元化的校园社区。

We have also established more than 20 NUS Overseas Colleges entrepreneurial hubs around the world..

我们还在全球建立了20多个国大海外学院创业中心。。

Our multidisciplinary and real-world approach to education, research and entrepreneurship enables us to work closely with industry, governments and academia to address crucial and complex issues relevant to Asia and the world. Researchers in our faculties, research centres of excellence, corporate labs and more than 30 university-level research institutes focus on themes that include energy; environmental and urban sustainability; treatment and prevention of diseases; active ageing; advanced materials; risk management and resilience of financial systems; Asian studies; and Smart Nation capabilities such as artificial intelligence, data science, operations research and cybersecurity.

我们的多学科和现实世界的教育，研究和创业方法使我们能够与工业界，政府和学术界密切合作，解决与亚洲和世界相关的关键和复杂问题。我们学院的研究人员，卓越研究中心，公司实验室和30多个大学级研究机构专注于包括能源在内的主题；环境和城市可持续性；治疗和预防疾病；积极老化；先进材料；风险管理和金融系统的抵御能力；亚洲研究；以及人工智能，数据科学，运营研究和网络安全等智能国家能力。

www.nus.edu.sg.

www.nus.edu.sg。

For media inquiries, please contact:

有关媒体查询，请联系：

Sarah SuttonArgot Partners[email protected]

Sarah SuttonArgot合伙人〔email protected〕

SOURCE 65LAB

来源65LAB